|
|
Volumn 470, Issue 7333, 2011, Pages 154-
|
|
Pfizer slashes R&D
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTILIPEMIC AGENT;
ATORVASTATIN;
GENERIC DRUG;
SILDENAFIL;
VACCINE;
CARDIOVASCULAR DISEASE;
COMPETITION;
COST CONTROL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
ECONOMIC ASPECT;
ERECTILE DYSFUNCTION;
HUMAN;
HYPERCHOLESTEROLEMIA;
INCOME;
INFLAMMATION;
NEUROSCIENCE;
NOTE;
ONCOLOGY;
PATENT;
PRIORITY JOURNAL;
UNITED KINGDOM;
VACCINATION;
BIOMEDICAL RESEARCH;
DRUG INDUSTRY;
DRUGS, GENERIC;
EMPLOYMENT;
HUMANS;
MARKETING;
PATENTS AS TOPIC;
|
|
EID: 79951469554
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/470154a Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
